

# Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

## Granzyme B antibody

RRID:AB\_304251

Type: Antibody

### Proper Citation

Abcam Cat# ab4059, RRID:AB\_304251

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_304251](http://antibodyregistry.org/AB_304251)

**Proper Citation:** Abcam Cat# ab4059, RRID:AB\_304251

**Target Antigen:** Granzyme B antibody

**Host Organism:** rabbit

**Clonality:** polyclonal

**Comments:** validation status unknown, seller recommendations provided in 2012: Immunohistochemistry - frozen; Flow Cytometry; Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunohistochemistry - fixed; Flow Cyt, ICC/IF, IHC-FoFr, IHC-P  
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

**Antibody Name:** Granzyme B antibody

**Description:** This polyclonal targets Granzyme B antibody

**Target Organism:** rat, mouse, human

**Antibody ID:** AB\_304251

**Vendor:** Abcam

**Catalog Number:** ab4059

**Record Creation Time:** 20231110T081435+0000

**Record Last Update:** 20260901T063549+0000

---

## Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Granzyme B antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 31 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Garczyk M, et al. (2026) Targeting PI3K $\gamma$  suppresses pancreatic cancer by dual disruption of fibrosis and immune evasion. Cell reports, 45(4), 117188.

Bui TM, et al. (2026) Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression. Cancer cell, 44(6), 1179.

Wei S, et al. (2026) A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell reports. Medicine, 7(4), 102716.

Yue S, et al. (2026) Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell.

Zeng Q, et al. (2026) Intratumoral Tertiary Lymphoid Structures Characterized by a B Cell-Related Signature Elicit Antitumor Effect through HAPLN3 in Hepatocellular Carcinoma. Cancer immunology research, 14(5), 771.

Qin Y, et al. (2026) Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma. Nature communications, 17(1).

Srinivasan S, et al. (2025) Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3662.

Liu Y, et al. (2025) Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer discovery, 15(1), 162.

Ding CH, et al. (2025) PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. *Cell death & disease*, 16(1), 158.

Hu SW, et al. (2025) Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer. *Cell reports. Medicine*, 6(11), 102429.

Ndjim M, et al. (2024) Tuft cell acetylcholine is released into the gut lumen to promote anti-helminth immunity. *Immunity*, 57(6), 1260.

Yurkina DM, et al. (2024) The Interaction of HMGB1 with the Proinflammatory TREM-1 Receptor Generates Cytotoxic Lymphocytes Active against HLA-Negative Tumor Cells. *International journal of molecular sciences*, 25(1).

Luckett T, et al. (2024) Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. *Cancer research*, 84(4), 527.

Chibaya L, et al. (2024) Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. *Science translational medicine*, 16(762), eadj9366.

Sakai Y, et al. (2023) Lethal severe fever with thrombocytopenia syndrome virus infection causes systemic germinal centre failure and massive T cell apoptosis in cats. *Frontiers in microbiology*, 14, 1333946.

Chen H, et al. (2023) EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression. *Cancer immunology research*, 11(6), 830.

Watanabe S, et al. (2023) In vivo transfection of cytokine genes into tumor cells using a synthetic vehicle promotes antitumor immune responses in a visceral tumor model. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 37(11), e23228.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Lupo KB, et al. (2023) TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma. *iScience*, 26(12), 108353.

Wen J, et al. (2022) Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. *EBioMedicine*, 86, 104371.